How to treat systemic necrotizing vasculitides?;Comment traiter une vascularite nécrosante?

Presse Medicale

Volumn 41, Issue 10, 2012, Pages 1024-1030

  Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

DISEASE CLASSIFICATION; DRUG PULSE THERAPY; HUMAN; MAINTENANCE THERAPY; NECROTIZING ARTERITIS; PRESCRIPTION; RECURRENCE RISK; REMISSION; SHORT SURVEY; SYSTEMIC NECROTIZING ARTERITIS; SYSTEMIC VASCULITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHOICE BEHAVIOR; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; POLYARTERITIS NODOSA; REMISSION INDUCTION; SYSTEMIC VASCULITIS;

EID: 84866362774     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.06.008     Document Type: Short Survey

References (33)

1. Guillevin L. Clinical trials on systemic necrotizing vasculitides. Presse Med 2010, 39(6):653-659.
2. Guillevin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumelin P. The five factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90(1):19-27.
3. Luqmani R.A. Assessing disease activity in the systemic vasculitides. Curr Opin Rheumatol 2002, 14(1):23-28.
4. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87(11):671-678.
5. Gayraud M., Guillevin L., Le Toumelin P., Cohen P., Lhote F., Casassus P., et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44(3):666-675.
6. Jarrousse B., Guillevin L., Bindi P., Hachulla E., Leclerc P., Gilson B., et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993, 11(6):615-621.
7. Godeau B., Mainardi J.L., Roudot-Thoraval F., Hachulla E., Guillevin L., Huong Du L.T., et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995, 54(12):991-994.
8. Le Guenno G., Mahr A., Pagnoux C., Dhote R., Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011, 63(5):1435-1445.
9. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116(6):488-498.
10. Gedalia A., Sorensen R. Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa. Clin Exp Rheumatol 1998, 16(6):767.
11. Guillevin L., Pagnoux C. Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int 2007, 56(2):105-111.
12. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Puechal X., et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010, 62(4):1186-1197.
13. Guillevin L., Cohen P., Mahr A., Arene J.P., Mouthon L., Puechal X., et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor-prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49(1):93-100.
14. Guillevin L., Mahr A., Callard P., Godmer P., Pagnoux C., Leray E., et al. virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005, 84(5):313-322.
15. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
16. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349(1):36-44.
17. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., Ducroix J.P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359(26):2790-2803.
18. Hiemstra T.F., Walsh M., Mahr A., Savage C.O., de Groot K., Harper L., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010, 304(21):2381-2388.
19. Stegeman C.A., Tervaert J.W., de Jong P.E., Kallenberg C.G. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335(1):16-20.
20. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18(7):2180-2188.
21. Jayne D.R., Lockwood C.M. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993, 336:469-472.
22. Martinez V., Cohen P., Pagnoux C., Vinzio S., Mahr A., Mouthon L., et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008, 58(1):308-317.
23. Etanercept plus standard therapy for Wegener's, granulomatosis. N Engl J Med 2005, 352(4):351-361.
24. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41(10):1126-1132.
25. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15(3):717-721.
26. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquieres G., Hayem G., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008, 67(9):1343-1346.
27. Al-Bishri J., Le Riche N., Pope J.E. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005, 32(7):1371-1373.
28. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Lauque D., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58(2):586-594.
29. Cohen P., Pagnoux C., Mahr A., Arene J.P., Mouthon L., Le Guern V., et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007, 57(4):686-693.
30. Sable-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005, 143(9):632-638.
31. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125(6):1336-1343.
32. Metzler C., Csernok E., Gross W.L., Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010, 28(1 Suppl. 57):24-30.
33. Tatsis E., Schnabel A., Gross W.L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998, 129(5):370-374.